Further weakness as Evotec drops 6.5 percent this week, taking three-year losses to 23 percent - Yahoo Finance
| EVT Stock | 8.41 0.06 0.72% |
Slightly above 51% of Evotec SE's private investors are presently thinking to get in. The analysis of current outlook of investing in Evotec SE suggests that some traders are interested regarding Evotec SE's prospects. Evotec SE's investing sentiment can be driven by a variety of factors including economic data, Evotec SE's earnings reports, geopolitical events, and overall market trends.
Evotec |
Further weakness as Evotec drops 6.5 percent this week, taking three-year losses to 23 Yahoo Finance
Read at news.google.com
 |
Evotec SE Fundamental Analysis
We analyze Evotec SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evotec SE using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evotec SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Evotec SE is rated below average in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Evotec SE Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Evotec SE stock to make a market-neutral strategy. Peer analysis of Evotec SE could also be used in its relative valuation, which is a method of valuing Evotec SE by comparing valuation metrics with similar companies.
Peers
Evotec SE Related Equities
| LP6 | LIVZON PHARMAC | 6.25 | ||||
| EVT | Evotec SE | 0.72 | ||||
| MRK | Merck KGaA | 0.18 | ||||
| H6D | Haleon PLC | 0.00 | ||||
| R2WA | BEXIMCO PHARMAGDR | 0.00 | ||||
| CJH | CanSino Biologics | 0.00 | ||||
| BSFA | ANI Pharmaceuticals | 0.00 | ||||
| S2P | SIMCERE PHARMAC | 0.00 | ||||
| DMP | Dermapharm Holding | 0.26 |
Additional Tools for Evotec Stock Analysis
When running Evotec SE's price analysis, check to measure Evotec SE's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evotec SE is operating at the current time. Most of Evotec SE's value examination focuses on studying past and present price action to predict the probability of Evotec SE's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evotec SE's price. Additionally, you may evaluate how the addition of Evotec SE to your portfolios can decrease your overall portfolio volatility.